0.802
0.04 (5.90%)
| Previous Close | 0.757 |
| Open | 0.770 |
| Volume | 1,400,267 |
| Avg. Volume (3M) | 1,915,069 |
| Market Cap | 64,240,120 |
| Price / Earnings (TTM) | 2.11 |
| Price / Earnings (Forward) | 0.870 |
| Price / Sales | 0.400 |
| Price / Book | 5.04 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | 23.08% |
| Operating Margin (TTM) | 46.41% |
| Diluted EPS (TTM) | 0.380 |
| Quarterly Revenue Growth (YOY) | 43.20% |
| Quarterly Earnings Growth (YOY) | 2,155.20% |
| Current Ratio (MRQ) | 1.25 |
| Operating Cash Flow (TTM) | -86.23 M |
| Levered Free Cash Flow (TTM) | -44.20 M |
| Return on Assets (TTM) | 9.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CytomX Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.21% |
| % Held by Institutions | 58.56% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Laurion Capital Management Lp | 31 Dec 2024 | 1,248,364 |
| 52 Weeks Range | ||
| Median | 2.50 (211.72%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 14 Apr 2025 | 2.50 (211.72%) | Buy | 0.606 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Apr 2025 | Announcement | CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting |
| 06 Mar 2025 | Announcement | CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update |
| 05 Mar 2025 | Announcement | CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference |
| 27 Feb 2025 | Announcement | CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |